Company Filing History:
Years Active: 2007
Title: **Inventor Gianpaolo Fogliatto: Innovating Biochemical Screening**
Introduction
Gianpaolo Fogliatto is an accomplished inventor based in Varese, Italy, known for his significant contribution to the field of biochemical screening. With a focus on enhancing drug-lead discovery, his innovative work employs advanced techniques to streamline the research process.
Latest Patents
Gianpaolo holds a patent for his method titled "Fluorine NMR spectroscopy for biochemical screening." This high-throughput screening (HTS) method is crucial in drug-lead discovery processes. The technology improves on a previously established biochemical NMR method, extending its application specifically to the screening of Ser/Thr kinases. By utilizing a CF moiety on the substrate, the method leverages fluorine NMR spectroscopy to detect both starting and enzymatically modified substrates. It allows experiments to be performed in real time or in an endpoint assay format, maintaining comparable protein and substrate concentrations to other HTS techniques. A notable application of his technique relates to the phosphorylation of a substrate by the Ser/Thr kinase AKT1, exemplifying the potential of his innovations in biochemical research.
Career Highlights
Fogliatto is currently affiliated with Pfizer Italia S.r.l., a leading pharmaceutical company that focuses on the development and commercialization of innovative medicines. His role within this prestigious organization has provided him the platform to advance his research and patent applications.
Collaborations
Throughout his career, Gianpaolo has collaborated with talented professionals such as Claudio Dalvit and Elena Ardini. Together, they contribute to the advancement of scientific knowledge and the development of new methodologies in biochemical research and drug discovery.
Conclusion
Gianpaolo Fogliatto exemplifies the spirit of innovation in the scientific community. His patent in fluorine NMR spectroscopy enhances the capabilities of biochemical screening, showcasing his commitment to improving the drug discovery process. With ongoing collaborations and a strong presence at Pfizer Italia S.r.l., he continues to pave the way for future advancements in the field.